甲哌啶嗪盐酸盐  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

库存{{model.attbuying.number}}
包装规格:25mg 50mg 100mg in glass bottle
溶解性:溶于DMSO(50 mg/mL 超声)
产品描述:基本信息 产品编号:M10795 产品名称:Mepazine hydrochloride CAS: 2975-36-2   储存条件 粉末 -20℃ 四年     分子式: C19H23ClN2S 溶于液体 -80℃ 六个月 分子量 346.92 -20℃ 一个月 化学名:      Solubility (25°C)   体外 DMSO   Ethanol   Water   体内(现配现用)     <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 3.1600mL 15.7998mL 31.5996mL 5mM 0.6320mL 3.1600mL 6.3199mL 10mM 0.3160mL 1.5800mL 3.1600mL   生物活性 产品描述 一种有效的选择性 MALT1 蛋白酶抑制剂。Mepazine hydrochloride 抑制全长 GSTMALT1 和 GSTMALT1 325-760 段的IC50 分别为 0.83 和 0.42μM。 靶点/IC50 10μM (TrKA phosphorylation) 1μM (ErbB2)   体外研究 Tyrphostin AG 879 (0.5-50μM; 48 hours;HL-60,U-937,PC-3,HTB-82,HTB-114,TE-671,HTB-115 and HTB-88 cells) treatment significantly and dose dependently decreases cell proliferation in all the cell lines.Tyrphostin AG 879 (0.5-50μM; 48 hours;HL-60,U-937,PC-3,HTB-82,HTB-114, TE-671, HTB-115 and HTB-88 cells) treatment also induces a dose-dependent increase in apoptosis with the exception of the lines TE-671 and HTB-88 cells. Cell Proliferation Assay Cell Line: HL-60, U-937, PC-3, HTB-82, HTB-114, TE-671, HTB-115 and HTB-88 cells Concentration: 0.5μM, 5μM, 20μM and 50μM Incubation Time: 48 hours Result: Significantly and dose dependently decreased cell proliferation in all the cell lines. Apoptosis Analysis Cell Line: HL-60, U-937, PC-3, HTB-82, HTB-114, TE-671, HTB-115 and HTB-88 cells Concentration: 0.5μM, 5μM, 20μM and 50μM Incubation Time: 48 hours Result: Induced a dose-dependent increase in apoptosis. 体内研究 Tyrphostin AG 879 (100mg/kg;subcutaneous injection; administered 10 times in 19 days; for 21 days; athymic,immunodepressed NOD/SCID female mice) treatment induces in vivo a decrease in cancer growth in grafted athymic NOD/SCID mice. Animal Model: Athymic, immunodepressed NOD/SCID female mice(20g) with HTB-114 and HL-60 cells Dosage: 100mg/kg Administration: Subcutaneous injection; administered 10 times in 19 days; for 21 days Result: Resulted in dramatic reductions in tumor sizes.
保存条件:-20℃